Cited by 227Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

Open access

Chu, Tianqing, Zhong, Runbo, Zhong, Hua, Zhang, Bo, Zhang, Wei, Shi, Chunlei, Qian, Jialin, Zhang, Yanwei, Chang, Qing, Zhang, Xueyan, Dong, Yu, Teng, Jiajun, Gao, Zhiqiang, Qiang, Huiping, Nie, Wei, Zhao, Yiming, Han, Yuchen, Chen, Ya, Han, Baohui·2021·Journal of Thoracic Oncology

DOI 10.1016/j.jtho.2020.11.026

Open this paper in CoChat — free account Open PDF

Abstract

Introduction Although the interaction between tumor immune microenvironment and angiogenesis has been well established, evidence supporting the chemo-free combination of immune checkpoint inhibitors plus antiangiogenic tyrosine kinase inhibitors in treatment-naive patients with advanced NSCLC is insufficient. This report provides the efficacy and safety of sintilimab combined with anlotinib as first-line therapy for advanced NSCLC from a phase 1b trial (NCT03628521).Methods Eligible patients who were treatment-naive and had unresectable stage IIIB/C or IV NSCLC without EGFR/ALK/ROS1 mutations received sintilimab (200 mg, day 1) and anlotinib (12 mg, day 1-14) every 3 weeks till disease progression or unacceptable toxicity. Baseline programmed death-ligand 1 expression and tumor mutation burden status was assessed in all patients. The primary end points were objective response rate and safety.Results A total of 22 patients received sintilimab and anlotinib. Median follow-up was 15.8 months (range: 8.3-19.3). Sixteen patients achieved confirmed partial response with an objective response rate of 72.7% (95% confidence interval [CI]: 49.8%-89.3%) and disease control rate of 100% (95% CI: 84.6%-100%). Median progression-free survival was 15 months (95% CI: 8.3 m, not reached), and the 12-month progression-free survival rate was 71.4% (95% CI: 47.2%-86.0%). The incidence rate of grade 3 or higher treatment-related adverse events was 54.5%, and grade 3 hypertension was predominant (two of 22, 9.1%). No grade 4 treatment-related adverse events were observed, and one case of grade 5 immune-related pneumonitis occurred.Conclusions To the best of our knowledge, this is the first study that assessed an anti-programmed cell death protein 1 antibody combined with a multitarget antiangiogenic tyrosine kinase inhibitor in the frontline setting for patients with NSCLC. In view of its encouraging efficacy, durability, and safety profile, sintilimab plus anlotinib represents a novel chemotherapy-free regimen in this patient population.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2020.11.026

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Mok, T. S. K., Wu, Y.-L. L. C., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., de Castro, G., Srimuninnimit, V., Лактионов, К. К., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,357
Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater
Reck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00149 · Cited by 1,670
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30167-6 · Cited by 1,662
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer
Gadgeel, S. M., Rodríguez‐Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., Hui, R., Hochmair, M. J., Clingan, P. R., Powell, S. F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03136 · Cited by 1,124
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez‐Abreu, D., Moro‐Sibilot, D., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30084-0 · Cited by 1,001

Flagged first, then by citations

Show all 37 references

1 of the 37 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 227

Clinical Efficacy of Antianlotinib Combined with Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small-Cell Lung Cancer and Its Effect on Serum VEGF, CEA, and SCC-Ag
He, L., Chen, X., Ding, L., & Zhang, X. (2022) · Journal of Oncology · doi:10.1155/2022/1530875 · Cited by 8
Self-citation
Immunotherapy in EGFR-mutant non-small cell lung cancer
Wang, L., Xian, X., Ke, H., & Wang, K. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01927-1 · Cited by 7
Efficacy of PD-1 Inhibitors Combined with Anti-Angiogenic Therapy in Driver Gene Mutation Negative Non-Small-Cell Lung Cancer with Brain Metastases
Song, J.-Q., Wang, X., Zeng, Z., Liang, P., Zhong, C., & Liu, A. (2023) · Discovery Medicine · doi:10.24976/discov.med.202335176.33 · Cited by 7
The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study
Yin, X., Liu, X., Ren, F., & Meng, X. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03712-7 · Cited by 8
The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases
Wu, X., Stabile, L. P., & Burns, T. F. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.06.004 · Cited by 7
Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort study
Shen, S., Li, X., Guo, S., Xu, L., & Yan, N. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1391828 · Cited by 7
Enhancing antitumor immunity: the role of immune checkpoint inhibitors, anti-angiogenic therapy, and macrophage reprogramming
Zhang, C., Wang, H., Li, X., Jiang, Y., Sun, G., & Yu, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1526407 · Cited by 8
Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification
Liu, Y., Long, L., Liu, J., Zhu, L., & Luo, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.749682 · Cited by 7
Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis
Xie, M., & Su, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1006284 · Cited by 7
Targeting serine synthesis pathway to reverse paclitaxel resistance in NSCLC with combination of paclitaxel and anlotinib
Yu, M., Hong, Y., Pan, Q., Zheng, P., He, Y., Zhu, W., Xu, S., & Lv, Q. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03627-w · Cited by 6
Case report: Successful treatment of advanced pulmonary sarcomatoid carcinoma with BUBIB-ALK rearrangement and KRAS G12C mutation by sintilimab combined with anlotinib
Huang, N., Qu, T., Zhang, C., & Li, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1269148 · Cited by 6
Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial
Zhang, C., Chu, T., Wang, Q., Cheng, Y., Zhang, Y., Wang, R., Ma, L., Qian, C., Han, B., & Li, K. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0423 · Cited by 6
Self-citation
Efficacy and safety of anlotinib monotherapy or combination therapy in the treatment of patients with advanced non-small cell lung cancer: a retrospective real-world study conducted in East China
Wei, J., Zhang, Y., Zheng, Y., Ma, C., Zhao, Q., Wang, Y., Miao, L., & Ding, J. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03635-8 · Cited by 6
Self-citation
Efficacy and safety of immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy for thymic epithelial tumors (TETs): a retrospective study
Xiang, J., Si, J., Hao, Y., Wei, J., Wang, W., Guan, Y., Xu, C., & Song, Z. (2023) · Translational Cancer Research · doi:10.21037/tcr-22-2192 · Cited by 6
Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming
Zou, B., Jiang, H., Liu, H., Lü, J., Qiang, H., Lu, M., Yu, L., Zhong, H., Chu, T., & Han, B. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300141 · Cited by 6
Self-citation
Treatment-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors in advanced lung cancer: A systematic review and meta-analysis
Zheng, Y., Dong, H., Yu, Y., Hu, Z., Xue, C., Zhang, X., & Cui, H. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110785 · Cited by 6
Self-citation
Corneal ulcer development due to sintilimab-anlotinib combination therapy-induced dry eye: a case report
Xiang, X., Lin, W., Guan, X., Zhou, B., Yuan, Y., Silva, D., & Wang, Y. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-1952 · Cited by 6
Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study
Zhang, B., Liu, H., Shi, C., Gao, Z., Zhong, R., Gu, A., Chu, T., Wang, H., Xiong, L., Zhang, W., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12479-0 · Cited by 6
Self-citation
Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer
Qi, W., Xi, D., Bai, Y., Liu, L., Ma, Y., Yin, Z., & Chen, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1026135 · Cited by 6
Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer
Zhang, C., Wang, J., Wang, X., Meng, Z., Cheng, Y., & Li, K. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0727 · Cited by 6
Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study
Nie, C., He, Y., Lv, H., Gao, M., Gao, X., Chen, B., Xu, W., Wang, J., Liu, Y., Zhao, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.885350 · Cited by 5
Severe Pulmonary Toxicity With Concurrent Anlotinib and Chemoradiotherapy in Stage III NSCLC: The ALTER-L042 Phase 1 Clinical Trial
Zhu, H., Jia, W., Jing, X., Huang, W., Wang, L., & Yu, J. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100339 · Cited by 5
DCZ19931, a novel multi-targeting kinase inhibitor, inhibits ocular neovascularization
Zhang, H., Li, B., Ding, J., Ye, R., Xu, Z., Zhang, Q., Feng, S.-G., Jiang, Q. L., Zhu, W., & Yan, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-25811-0 · Cited by 5
Efficacy and safety analysis of anlotinib combined with PD-1 inhibitors in advanced non-small cell lung cancer: a retrospective cohort study
Ye, X., Huang, A., Zhou, Y., Kuang, Y., Wang, W., Gu, A., & Xu, L. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-289 · Cited by 5
Current immune therapeutic strategies in advanced or metastatic non-small cell lung cancer
Xu, J., Liu, C., Wu, X., & Ma, J. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002536 · Cited by 6
Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients
Chen, Y., Jiang, N., Liang, X., Chen, N., Chen, Y., Zhang, C., Shi, J., & Guo, R. (2023) · Oncology Letters · doi:10.3892/ol.2023.13909 · Cited by 5
Self-citation
The efficacy and safety of chemo‐free therapy in epidermal growth factor receptor tyrosine kinase inhibitor‐resistant advanced non‐small cell lung cancer: A single‐arm, phase II study
Zhang, S., Yang, L., Yang, Y., Yang, G., Xu, H., Niu, X., & Wang, Y. (2023) · Cancer Medicine · doi:10.1002/cam4.6545 · Cited by 6
Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review
Wen, Y., Dong, Y., Yi, L., Yang, G., Xiao, M., Li, Q., Zhao, C., Ye, D., & Yao, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1241475 · Cited by 5
Self-citation
Efficacy and toxicity of anlotinib plus camrelizumab versus anlotinib plus S-1 as second-line therapy for advanced esophageal squamous cell carcinoma: A real-world retrospective study
Zhang, W., Chen, M., Dai, H., & Sun, W. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.12.003 · Cited by 5
Self-citation
Anlotinib synergizes with venetoclax to induce mitotic catastrophe in acute myeloid leukemia
Wang, D., He, J., Liu, S. M., Zhang, H., Tang, D., Chen, P., & Yang, M. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216970 · Cited by 5
Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib
Fu, C., Du, H., Wang, Q., Zhu, W., Bian, G.-L., Zhong, Z., Wang, Y., & Cao, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1452195 · Cited by 5
Efficacy and safety profile of combining programmed cell death‐1 ( PD ‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer ( NSCLC )
Xu, Z., Li, T., Hu, X., Hao, X., Xing, P., & Li, J. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14078 · Cited by 5
[Anti-angiogenesis in Lung Cancer: Current Situation, Progress and Confusion].
Zhou, J., & Chen, J. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.101.16 · Cited by 5
Low-dose anlotinib plus immune checkpoint inhibitors offers better efficacy and safety in advanced non-small cell lung cancer treatment
Tan, T., Yuan, S., Chu, W., Jiang, J., Chen, M., Xia, Q., & Wang, J. (2025) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001701 · Cited by 4
Effectiveness and Safety of Anlotinib-Related Therapeutic Regimens in Patients with Previously Immune Checkpoint Inhibitors-Treated Advanced NSCLC: A Real-World Exploratory Study
Fang, X.-S., Zhang, T., Li, S., Zhao, Y.-L., Li, J., Xia, H., & Wang, R. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s535615 · Cited by 4
Self-citation
Anlotinib promotes CD4 + T cell infiltration and enhances the anti-tumor effect of PD-1 blockade in lung cancer
Zhang, M., Liu, L., Zheng, H., Chen, M., & Li, J. (2025) · Immunologic Research · doi:10.1007/s12026-025-09621-w · Cited by 4
Distinct survival, optimal combination strategy of immunotherapy, and immunophenotype in uncommon and 20ins EGFR-mut lung adenocarcinoma: a multi-center study
Sun, Y., Xu, L., Deng, C., Du, X., Yu, Y., Yuan, H., Wang, H., Wang, X., Zhang, Y., & Chen, H. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00331-1 · Cited by 4
Self-citation
Efficacy of argon–helium cryoablation combined with PD-1 inhibitors in non-small cell lung cancer
Zheng, Z., Tian, B., An, Y., Wang, W., Zhang, M., Ma, W., Guo, Y. Q., Fan, Y., & Li, N. (2025) · Acta Oncologica · doi:10.2340/1651-226x.2025.44215 · Cited by 4
A Linear Discriminant Analysis Model Based on the Changes of 7 Proteins in Plasma Predicts Response to Anlotinib Therapy in Advanced Non-Small Cell Lung Cancer Patients
Xu, F., Xu, H., Wan, Z., Yang, G., Lü, Y., Wu, X., Song, J. S., & Wang, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.756902 · Cited by 4
Anlotinib Enhances the Therapeutic Effect of Bladder Cancer with GSDMB Expression: Analyzed from TCGA Bladder Cancer Database & Mouse Bladder Cancer Cell Line
Wang, C., Cao, Q., Zhang, S., Liu, H., Duan, H., Xia, W., Shen, H., & Wang, C. (2023) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s398451 · Cited by 4
Osteoblastic Bone Reaction Developing During Treatment With Sintilimab and Bevacizumab in a Patient With KRAS G12V-Mutant Lung Adenocarcinoma
Chen, C., Zhao, X., Zhao, J., Xiao, J., Xu, W. H., Qi, Y. B., Li, J. K., Ma, Q. W., Zhang, L., & Yang, Y. P. (2023) · World Journal of Oncology · doi:10.14740/wjon1702 · Cited by 4
Case report: Combination therapy of envafolimab with endostar for advanced non-small cell lung cancer with low PD-L1 expression
Wu, S., Dong, C., Hu, C., Hui, K., & Jiang, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1437260 · Cited by 4
Efficacy and safety of combining anti-angiogenic therapy, radiotherapy, and PD-1 inhibitors in patients with driver gene-negative non-small cell lung cancer brain metastases: a retrospective study
Zhang, X., Sun, Q., Chen, R., Zhao, M., Cai, F., Cui, Z., & Jiang, H. (2024) · BMC Cancer · doi:10.1186/s12885-024-13264-9 · Cited by 4
Self-citation
Ivonescimab in non-small cell lung cancer: harmonizing immunotherapy and anti-angiogenesis
Zhang, Y., Liu, X., & Ren, S. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2487512 · Cited by 4
Self-citation
A Critical Review of Immunomodulation in the Management of Inoperable Stage III NSCLC
Burcher, K. M., Karukonda, P., Kelsey, C. R., Mullikin, T. C., Antonia, S. J., & Oduah, E. (2025) · Cancers · doi:10.3390/cancers17111829 · Cited by 4
Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report
Wang, J., Li, X., Zhou, J., Qiu, D., Zhang, M., Lan, S., & Li, S. C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1043244 · Cited by 4
Efficacy and Safety Analysis of Immune Checkpoint Inhibitors plus Angiogenesis Inhibitors for the Treatment of Advanced Driver-negative NSCLC in Elderly Patients: A Retrospective Study
Zhang, J., Zou, Z., Tan, J., Shi, J., Yang, H., Wang, H., Zhou, J., & Xue, J. (2023) · Journal of Cancer · doi:10.7150/jca.83719 · Cited by 4
Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial
Wang, Z., Qin, B., Ye, C.-Y., Wang, M., Yuan, L., Yao, H., Jiao, X., Liu, K., Zhou, W., Qin, W., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02383-9 · Cited by 3
Self-citation
[Research Progress of Adverse Events Related to PD-1/PD-L1 Inhibitors Based Combination Therapy].
Guo, X., Wen, T., & Qu, X. (2021) · PubMed Central · doi:10.3779/j.issn.1009-3419.2021.101.26 · Cited by 3
Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers
An, T., Qiu, H., Zong, H., Liu, L., Cao, X., Li, R., Hu, S., Liu, Y., Li, J., & Zhao, R. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03425-4 · Cited by 3
Efficacy and safety of anlotinib as maintenance treatment in extensive-stage small cell lung cancer: a single-armed single center retrospective study
Xiong, J., & Xia, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1462581 · Cited by 3
Dramatic response of advanced pulmonary sarcomatoid carcinoma to tislelizumab combined with anlotinib: a case report
Li, R., Di, X., Li, Y., Li, H., & Liu, C. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1531700 · Cited by 3
[Review on the Combination Strategy of Anti-angiogenic Agents and Other Anti-tumor Agents in Advanced Non-small Cell Lung Cancer].
Xu, Z., & Li, J. (2021) · PubMed Central · doi:10.3779/j.issn.1009-3419.2021.101.16 · Cited by 3
Establishment and validation of a LC–MS/MS method for the determination of anlotinib in human plasma: Application to therapeutic drug monitoring
Yu, M., Liang, Z., Xiong, L., Liu, F., Cheng, L., Jia, C., Qi, X., & Sun, F. (2022) · Biomedical Chromatography · doi:10.1002/bmc.5501 · Cited by 3
Anlotinib in patients with relapsed or refractory thymic epithelial tumors: a study of 50 cases
Wang, C., Zhao, Y., Zhang, Q., Zeng, W., Jia, T.-Y., Zhu, L., Fang, W., & Fu, X. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001473 · Cited by 3
Self-citation
Efficacy and safety of PD‑1 inhibitor plus antiangiogenic treatment in patients with unresectable biliary tract cancer: A multicenter retrospective study
Wu, Z., Zhu, X., Zhong, X., Wang, Y., Zheng, Y., Han, W., Pan, H., & Yao, J. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12051 · Cited by 3
Anlotinib plus Sintilimab achieved in an antitumor effect of complete remission in a patient with advanced hepatocellular carcinoma: a case report
Sun, C., Ma, X., Jiang, L., & Zhu, X. (2024) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001567 · Cited by 3
Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy
Chen, K., Li, S., Chen, M., Jin, Z., Sun, X., Zhou, S., & Yang, H. (2024) · BMC Cancer · doi:10.1186/s12885-024-12001-6 · Cited by 3
Immunotherapy combined with antiangiogenic therapy as third‐ or further‐line therapy for stage IV non‐small cell lung cancer patients with ECOG performance status 2: A retrospective study
Li, S., Yu, Z., Liu, H., Li, S., Wang, M., Ning, F., & Tian, L. (2024) · Cancer Medicine · doi:10.1002/cam4.7349 · Cited by 3
An Open‐Label, Single‐Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non‐Small Cell Lung Cancer After First‐Line PD ‐(L)1 Inhibitor
Shi, X., Chen, L., Lou, L., He, Q., Lou, G., Hong, W., Shao, L., Zhao, J., Gu, C., Yu, X., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71191 · Cited by 3
TQB2450 with or without anlotinib as maintenance treatment in subjects with locally advanced/unresectable non-small cell lung cancer that have not progressed after prior concurrent/sequential chemoradiotherapy (R-ALPS): study protocol for a randomized, double-blind, placebo-controlled, multicenter phase III trial
Dong, B., Chen, L., Pang, Q., Jiang, O., Ge, H., Cheng, Y., Zhou, R., Meng, X., Li, J., Zhu, X., et al. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-362 · Cited by 3
Where Do We Go With the Combination of Immune Checkpoint Inhibitors With Anti-Angiogenesis in Advanced NSCLC?
Wang, F., & Adjei, A. A. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.06.031 · Cited by 2
A rapid response of lung squamous cell carcinoma following treatment with sintilimab combined with recombinant humane endostatin injection and nab-paclitaxel in an elderly patient
Fang, Y., Sun, H., Chen, Y., Jiang, N., Ji, L., & Shi, J. (2021) · Medicine · doi:10.1097/md.0000000000026801 · Cited by 2
Self-citation
[An Overview and Interpretation of Important Clinical Studies on Non-small Cell Lung Cancer in 2021].
Gan, B. Q., Liu, S. M., & Wu, Y.-L. L. C. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.101.19 · Cited by 2
Efficacy of Immunotherapy Combined with Antiangiogenic Therapy in Treatment-Failure Patients with Advanced Carcinoma Ex Pleomorphic Adenoma of the Submandibular Gland: A Case Report
Sa, H., Xu, Y., Ma, X., Wang, X., Sun, C., Qiu, S., Guo, Y., Yang, Z., Liu, Y., & Ma, K. (2022) · Current Oncology · doi:10.3390/curroncol29090498 · Cited by 2
Efficacy and safety of immune checkpoint inhibitors plus recombinant human endostatin therapy as second-line treatment in advanced non-small-cell lung cancer with negative driver gene: a pilot study
Yang, B. Y., Li, Y., Deng, J., Yang, H. J., & Sun, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1210267 · Cited by 2
Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive‐stage small‐cell lung cancer patients (DURABLE study)
Zhang, B., Zhong, H., Shi, C., Gao, Z., Zhong, R., Gu, A., Wang, W., Chu, T., Xiong, L., Zhang, W., et al. (2023) · The Clinical Respiratory Journal · doi:10.1111/crj.13715 · Cited by 2
Self-citation
Primary Pulmonary Lymphoepithelioma-like Carcinoma: A Case Report Utilizing Camrelizumab and Anlotinib for Prolonged Survival
Lei, S., Tian, S., Lu, S., Zhou, Q., Long, J., Li, L., & Yang, D. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206294031240404071838 · Cited by 2
Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC
Bao, Z., Yu, X., Zheng, K., Zhai, K., Cui, H., & Xu, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1372279 · Cited by 2
Efficacy and safety of anlotinib in combination with immune checkpoint inhibitors or not as advanced non-small cell lung cancer treatment: a systematic review and network meta-analysis
Wu, Z., Zhou, P., Zhao, Y., Wang, J., & Gao, S. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-1483 · Cited by 2
Self-citation
Comparison of clinical outcomes in patients with advanced pulmonary sarcomatoid carcinoma treated with immunotherapy-based regimens or chemotherapy: A study based on the SEER database and multicentric real-world settings
Peng, D., Xiong, L., Luo, Y., Chen, J., Zheng, Y., Zeng, X., Liu, S., Liu, A., Wang, X., & Zeng, Z. (2024) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_479_24 · Cited by 2
Efficacy and Safety of Immunotherapy Combined with Anlotinib as First-Line Treatment in Older NSCLC Patients with PD-L1 Expression<50%
Li, X., Wang, W., Xu, C., & Yuan, Q. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096364469250113105648 · Cited by 2
Case Report: A long-term response of immunotherapy combined with anti-angiogenesis therapy in a patient with dMMR metastatic colorectal cancer after ICI failure
Huang, Q., Zheng, X., & Xu, W. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1553380 · Cited by 2
Case Report: Dialysis following sintilimab-induced stage 3 acute kidney injury: mechanism investigation and management strategies
Shan, B., Li, M., Yang, R., Wang, G., Hou, J., & Wen, T. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1632740 · Cited by 2
The Role of PD-L1 Expression in Prediction and Stratification of Recurrent or Refractory Extranodal Natural Killer/T-Cell Lymphoma
Gao, L., Zhang, Y.-H., Shi, X., Liu, Y., Wang, J., Zhang, W., & Liu, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.821918 · Cited by 2
Self-citation
Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
Zhang, D., Liang, J., Lv, Y., Huang, X., & Guo, W. (2022) · Medicine · doi:10.1097/md.0000000000032459 · Cited by 2
Hypothyroidism induced by immune checkpoint inhibitors combined with antiangiogenic agents is associated with higher body mass index
Wang, X., Chen, X., Zhou, J., & Jiang, R. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-306 · Cited by 2
Panoramic Tissue Examination That Integrates 3-Dimensional Pathology Imaging and Gene Mutation: Potential Utility in Non–Small Cell Lung Cancer
Wang, L., Hsieh, Y.-H., Hung, Y.-L., Jiang, Y., Lin, Y., Chang, M. D., Lin, Y.-Y., & Chou, T. (2023) · Laboratory Investigation · doi:10.1016/j.labinv.2023.100195 · Cited by 3
Case report: outcome of anlotinib treatment in breast cancer patient with brain metastases
Zhang, Q., Yan, X., Tian, T., & Wu, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1381478 · Cited by 2
Too Good to be True?
Sebastian, M., Stratmann, J., & Eberhardt, W. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.1606 · Cited by 2
Anti-Angiogenic Agents Combined with Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Lin, H., Ma, C., Zhong, A., Zang, H., Chen, W., Li, L., Le, Y., & Xie, Q. (2023) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207326666230808112656 · Cited by 1
TACE combined with portal particle implantation in a case of stage IIIa primary hepatocellular carcinoma treated with sequential anlotinib
Cheng, L., Chen, C., Huang, G., Li, Y., Zhao, L., & Wei, Z. (2023) · Journal of Contemporary Brachytherapy · doi:10.5114/jcb.2023.131239 · Cited by 1
Synergistic effect of additional anlotinib and immunotherapy as second‐line or later‐line treatment in pancreatic cancer: A retrospective cohort study
Qin, B., Xiong, Q., Xin, L., Li, K., Shi, W., Song, Q., Sun, Q., Shao, J., Zhang, J., Zhao, X. Q., et al. (2024) · Cancer Innovation · doi:10.1002/cai2.123 · Cited by 1
Combined BRAF G469A mutation and echinoderm microtubule associated protein like-4-anaplastic lymphoma kinase rearrangement with resistance: A case report and review of literature
Guo, X., Liu, Y., Wang, Y., Liu, K., & Ding, H. J. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i2.98812 · Cited by 1
Penpulimab and Anlotinib in PDL1 high-expression pulmonary giant cell carcinoma with cerebral metastases: case report and review
Xie, M., Zhao, Y., Hou, X., Li, N., Niu, S., & Xu, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1476205 · Cited by 1
Self-citation
FGFR-driven lung cancer: Dissecting resistance and exploring therapeutic avenues
Zhang, P., Mei, W., Yao, Y., Zeng, C., & Li, W. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105205 · Cited by 1
Dynamic alterations of ctDNA associate with the therapeutic outcome in the advanced non‐small cell lung cancer patients who received sintilimab plus anlotinib regime as 1st line therapy
Chu, T., Yuan, J., Lü, J., Nie, W., Zhong, R., Zhang, B., Zhang, W., Shi, C., Qian, J., Zhang, Y., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1277 · Cited by 1
Self-citation
Case report: Massive hepatocellular carcinoma with complete response to the non-surgical systematic treatment strategy
Li, Y., Lai, Y., Luo, X., Wu, J., Wu, K., & Ma, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1291131 · Cited by 1
A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: A case report and literature review
Liu, Y., Li, M., Guo, Y., Zhang, Z., Du, L., Zhang, X., Wang, Y., Zhang, D., Xue, L., Lei, B., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155371 · Cited by 1
Self-citation
Enhancing safety and therapeutic efficacy: PD-1 inhibitor and recombinant human endostatin combination in advanced non-small cell lung cancer patients
Wang, S. (2024) · American Journal of Translational Research · doi:10.62347/pnqt4160 · Cited by 1
Case Report: Efficacy of anlotinib and sintilimab in treating lung adenocarcinoma with RET fusion and PD-L1 expression
Bao, H., Zhang, J., Wang, Y., Chen, Z., Luo, X., Li, T., Su, H., Bao, H., Cao, X., & Lin, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1448291 · Cited by 1
Immuno-oncological Challenges and Chemoresistance in Veterinary Medicine: Probiotics as a New Strategic Tool
Nisar, M. F., Yan, T., Cai, Y., & Wan, C. C. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10468-8 · Cited by 2
Treatment strategies for rapid recurrence and progression after surgery for stage I pulmonary pleomorphic carcinoma: a case report and literature review
Zhang, J., Xiong, W., Wang, H., Sun, L., Chen, C., Sun, X., Man, X., Lei, Y., & Li, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1547872 · Cited by 1
Camilo J. Cela, "autotradutor" ao galego de La familia de Pascual Duarte
Dasilva, X. M. (2010) · Repositorio institucional da Universidade de Santiago de Compostela (University of Santiago de Compostela)
Long-Term Survival of PD-1 Inhibitor Combined with Antiangiogenic Agents in a Patient with Pulmonary Sarcomatoid Carcinoma Complicated with Esophageal Cancer: A Case Resport and Literature ReviewPreprint
Jiao, S., Zhang, X., Wang, R., Zhu, H. L., Li, S., & Tang, H. (2021) · Research Square · doi:10.21203/rs.3.rs-1113754/v1
Self-citation
Data from Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma
Su, Y., Luo, B., Lu, Y., Wang, D., Yan, J., Zheng, J., Xiao, J., Wang, Y., Xue, Z., Yin, J., et al. (2023) · doi:10.1158/1078-0432.c.6531219.v1
Prognostic and Predictive Markers for Immunotherapy in Non Small Cell Lung Cancer
Filip, V. P., & Farcas, M. F. (2023) · Journal of Medical and Radiation Oncology · doi:10.53011/jmro.2023.01.02
Dramatic response of a negative PD-L1 expression and TMB low pulmonary sarcomatoid carcinoma to sintilimab combined with anlotinib
Liuone, L. (2023) · Open Journal of Clinical and Medical Case Reports · doi:10.52768/2379-1039/1969
Anlotinib: A Novel Molecular-Targeted Drug for Tumours
Na, J., Liu, X., Sun, X., Fan, D., Qian, Z., Yao, M., Pan, L., He, Z., Liu, Q., Shen, Z., et al. (2023) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2023.3639
The Metabolic Subtypes of Gastric Cancer Reveal Treatment PreferencesPreprint
Zhou, Q., Yuan, Y., Yue, Z., Lu, H., Liu, Z., Sheng, J., & Xin, L. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4526542

Authors: Chu, T., Zhong, R., Zhong, H., Zhang, B., Zhang, W., Shi, C., Qian, J., Zhang, Y., Chang, Q., Zhang, X., Dong, Y., Teng, J., Gao, Z., Qiang, H., Nie, W., Zhao, Y., Han, Y., Chen, Y., & Han, B.
Affiliations: Shanghai Jiao Tong University (CN)
Corresponding author: Han, Baohui
ORCID: Chu, Tianqing
Zhong, Runbo
Zhong, Hua
Zhang, Bo
Zhang, Wei
Shi, Chunlei
Qian, Jialin
Zhang, Yanwei
Chang, Qing
Zhang, Xueyan
Dong, Yu
Teng, Jiajun
Gao, Zhiqiang
Nie, Wei
Zhao, Yiming
Han, Yuchen
Chen, Ya
Han, Baohui
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2021-04
Volume: 16
Issue: 4
Pages: 643-652
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1016/j.jtho.2020.11.026
OpenAlex: W3126928179
Cited by: 227
References: 37
Citations by year: 2026: 11 · 2025: 35 · 2024: 56 · 2023: 53 · 2022: 54 · 2021: 17
FWCI: 16.38
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
Locations: Journal of Thoracic Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: Science and Technology Commission of Shanghai Municipality (18411968500)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: sintilimab, anlotinib, non-small cell lung cancer, first-line therapy, immune checkpoint inhibitors, antiangiogenic tyrosine kinase inhibitors, anti-PD-1 therapy, combination immunotherapy, chemotherapy-free regimen, tumor immune microenvironment, tumor angiogenesis, objective response rate, progression-free survival, treatment-related adverse events, hypertension, immune-related pneumonitis, PD-L1 expression
MeSH terms: Antineoplastic Combined Chemotherapy Protocols, Humans, Indoles, Lung Neoplasms, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Quinolines, Tumor Microenvironment, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks